European Journal of Cancer
Volume 46, Issue 1 , Pages 160-169 , January 2010

Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989

  • Michael Schaapveld

      Affiliations

    • Comprehensive Cancer Center Amsterdam (CCCA), P.O. Box 9236, 1006 AE Amsterdam, The Netherlands
    • Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Address: Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel.: +31 20 512 2488; fax: +31 20 512 2322.
    • ,
  • Otto Visser

      Affiliations

    • Comprehensive Cancer Center Amsterdam (CCCA), P.O. Box 9236, 1006 AE Amsterdam, The Netherlands
    • ,
  • Sabine Siesling

      Affiliations

    • Comprehensive Cancer Center North East (CCCNE), P.O. Box 330, 9700 AH Groningen, The Netherlands
    • ,
  • Cees G. Schaar

      Affiliations

    • Department of Internal Medicine, Gelre Hospitals, P.O. Box 9014, 7300 DS, Apeldoorn, The Netherlands
    • ,
  • Sonja Zweegman

      Affiliations

    • Department of Hematology, VU Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • Edo Vellenga

      Affiliations

    • Department of Hematology, University Medical Center Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands

Received 20 May 2009 ,Revised 15 July 2009 ,Accepted 17 July 2009.

References 

  1. Association of Comprehensive Cancer Centres [homepage on the Internet]. Utrecht: The Netherlands. http://www.ikcnet.nl/cijfers/index.php?taal=nl&frequentiemaat=1&regio=Landelijk&soort_kanker=50&soort_morfologie=&periode=2005&inputRegioLandelijk=on&inputRegioMZ=&fInvasief=1&uitkomstmaat=2&periode_input=2005&leeftijdsklassen=1.
  2. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208:1680–1685
  3. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989;2:882–885
  4. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992;10:334–342
  5. Abrahamson GM, Bird JM, Newland AC, et al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol. 1996;94:659–664
  6. Jagannath S, Barlogie B, Dicke K, et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood. 1990;76:1860–1866
  7. Bladé J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol. 1996;14:2167–2173
  8. Tribalto M, Amadori S, Cudillo L, et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica. 2000;85:52–58
  9. Hovenga S, de Wolf JT, Guikema JE, et al. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant. 2000;25:723–728
  10. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–831
  11. Facon T, Mary JY, Hulin C, et al. Intergroupe Francophone du Myélome Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209–1218
  12. San Miguel JF, Schlag R, Khuageva NK, et al. VISTA Trial Investigators Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med. 2008;359:906–917
  13. DurieSalmon SE BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36:842–854
  14. Schaar CG, Kluin-Nelemans HC, Te Marvelde C, et al. Dutch–Belgian Hemato-Oncology Cooperative Group HOVON Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol. 2005;16:634–639
  15. Segeren CM, Sonneveld P, van der Holt B, et al. Dutch–Belgian Hemato-Oncology Cooperative Study Group Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood. 2003;101:2144–2151
  16. Sonneveld P, van der Holt B, Segeren CM, et al. Dutch–Belgian Hemato-Oncology Cooperative Group (HOVON) Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica. 2007;92:928–935
  17. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Dutch–Belgian HOVON; German GMMG Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008;93:124–127
  18. Lokhorst H, Huijgens PC, Raymakers R, et al. Myeloomwerkgroep van de Stichting Hemato-Oncologie voor Volwassenen Nederland Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]. Ned Tijdschr Geneeskd. 2005;149:808–813
  19. Hovenga S, Daenen SM, de Wolf JT, et al. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann Hematol. 2005;84:311–316
  20. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520
  21. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521–2526
  22. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25:1993–1999
  23. Carli PM, Coebergh JW, Verdecchia A. Variation in survival of adult patients with haematological malignancies in Europe since 1978. Eur J Cancer. 1998;34:2253–2263
  24. Sant M, Allemani C, Santaquilani M, et al., EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 2009; 45:931–91.
  25. Hébert-Croteau N, Brisson J, Lemaire J, Latreille J. The benefit of participating to clinical research. Breast Cancer Res Treat. 2005;91:279–281
  26. Du Bois A, Rochon J, Lamparter C, Pfisterer J AGO Organkommission OVAR PFisterer. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer. 2005;15:183–191

PII: S0959-8049(09)00543-7

doi: 10.1016/j.ejca.2009.07.006

European Journal of Cancer
Volume 46, Issue 1 , Pages 160-169 , January 2010

Article Tools

* Image Usage & Resolution